Institutional power play in innovation systems: The case of Herceptin®
Institutional power play in innovation systems: The case of Herceptin®
复制标题
DOI：
10.1016/j.respol.2016.01.016
复制
发表时间：
2016-10-01
期刊：
影响因子：
7.2
通讯作者：
Hekkert, Marko P.
中科院分区：
文献类型：
--
作者：
Kukk, Piret;Moors, Ellen H. M.;Hekkert, Marko P.
新技术必须伴随着体制变革。因此，创新行为者需要从事机构工作，或发挥机构企业家的作用，以便根据其技术的最佳利益塑造机构。然而，关于制度建设和制度创业的文献很少有重叠之处。本文的目标是弥合这两个机构的文献，以获得更多的见解如何在技术创新系统的制度变迁演变。我们将展示罗氏制药公司如何作为一个强大的机构企业家，影响英国的医疗保健系统，为个性化的癌症药物赫赛汀创造一个市场。我们证明，制度变革之前，可以通过一系列的创新体系建设活动，不直接旨在带来制度变革，但需要为了制度变革的发生。通过这一案例研究，我们展示了制度建设和制度变迁文献如何相辅相成。(C)2016作者由爱思唯尔公司出版。这是一篇开放获取的文章，获得了CC BY-NC-ND许可证（http：//creativecommons.org/licenses/by-nc-nd/4.0/）。
New technologies must be accompanied by institutional change. Innovative actors therefore need to do institutional work or take a role as an institutional entrepreneur in order to shape the institutions in the best interests of their technology. However, the literature on system building and on institutional entrepreneurship have little overlap. The goal of this paper is to bridge these two bodies of literature to gain additional insights into how institutional change evolves in a technological innovation system. We show how the pharmaceutical firm Roche acted as a powerful institutional entrepreneur by influencing the health-care system in England to create a market for the personalized cancer drug Herceptin. We demonstrate that institutional change can be preceded by a range of innovation system-building activities that are not directly intended to bring about institutional change but are required in order for institutional change to take place. Through this case study, we show how the system-building and institutional change literature can complement each other. (C) 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).